Veeva and Merck form long-term strategic partnership

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Merck and Moderna Inc. have initiated the phase III randomized INTerpath-002 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda as adjuvant treatment in patients with completely resected (R0) Stage II, IIIA or IIIB (with nodal involvement [N2]) non-small cell lung cancer. 
In a prespecified interim analysis of the phase III LITESPARK-005 trial, Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Afinitor (everolimus) in adult patients with advanced renal cell carcinoma that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor therapies.

Login